CD40LG and pancreatic ductal adenocarcinoma: A phase 1/2 clinical investigation demonstrated the feasibility and safety of LOAd703, an oncolytic adenovirus carrying transgenes encoding TMZ-CD40L and 4-1BBL, in combination with nab-paclitaxel and gemcitabine for treating patients with advanced pancreatic ductal adenocarcinoma (16).